Having -c(=x)-, Wherein X Is Chalcogen, Bonded Directly To Carbon Of The Hetero Ring Of The Quinoline Ring System Patents (Class 514/253.08)
  • Patent number: 10376508
    Abstract: Methods of treatment of NTM lung infections using formulations of liposomal ciprofloxacin. Specific liposome formulations and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: August 13, 2019
    Assignees: ARADIGM CORPORATION, OREGON STATE UNIVERSITY
    Inventors: Igor Gonda, James Blanchard, David C. Cipolla, Luiz Eduardo Moreira Bermudez
  • Patent number: 10231925
    Abstract: The invention relates to the use of quaternary ammonium compounds for preventing precipitations of fluoroquinolones from their solutions and to stable, tolerated pharmaceuticals which are particularly suitable for parenteral use and which contain, in dissolved form, a fluoroquinolone and a quaternary ammonium compound.
    Type: Grant
    Filed: February 23, 2007
    Date of Patent: March 19, 2019
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Iris Heep, Kristine Fraatz, Hans-Jürgen Hamann, Markus Edingloh
  • Patent number: 10159670
    Abstract: A method of treating a cellular stress-related disease in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of an agent capable of enhancing processing of a pre-miRNA, thereby treating the cellular stress-related disease in the subject. Methods for treating motor neuron disease (MND) are also provided as well as pharmaceutical compositions.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: December 25, 2018
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Eran Hornstein, Anna Maria Emde
  • Patent number: 9750764
    Abstract: The inventions discloses a trace element solution, which comprises at least the following metals: zinc; manganese; selenium; and copper; and which comprises a concentration of the metals of at least 90 mg/ml. The solution may comprise the following concentrations: at least 60 mg/ml zinc; at least 10 mg/ml manganese; at least 5 mg/ml selenium; and at least 15 mg/ml copper. The solution may comprise chromium, iodine and chromium.
    Type: Grant
    Filed: November 30, 2009
    Date of Patent: September 5, 2017
    Assignee: WARBURTON TECHNOLOGY LIMITED
    Inventor: William Alfred Smith
  • Patent number: 9730910
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: August 15, 2017
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
  • Patent number: 9670179
    Abstract: Embodiments of the present disclosure provide for compositions including an antibiotic containing a N-thiolated beta-lactam moiety, pharmaceutical compositions including the antibiotic, methods of treatment of a condition (e.g., bacterial infection), methods of treatment using compositions or pharmaceutical compositions, and the like.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: June 6, 2017
    Assignee: University of South Florida
    Inventors: Edward Turos, Biplob Bhattacharya
  • Patent number: 9603796
    Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: March 28, 2017
    Assignees: OTONOMY, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jay Lichter, Andrew M. Trammel, Fabrice Piu, Qiang Ye, Luis A. Dellamary, Carl Lebel, Jeffrey P. Harris
  • Patent number: 9415111
    Abstract: The invention relates to novel luminescent compositions of matter containing two fluorophores (sensitizers), synthetic methods for making the compositions, macromolecular conjugates of the compositions, and the use of the compositions and their conjugates in various methods of detection. The invention also provides kits containing the compositions and their conjugates for use in the methods of detection.
    Type: Grant
    Filed: August 11, 2007
    Date of Patent: August 16, 2016
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Arkady Mustaev, Salvatore A. E. Marras
  • Patent number: 9084740
    Abstract: This invention relates to methods and compositions for degrading collagen in mammalian skin, thereby improving the appearance and/or reducing the size of a closed wound, which may be a scar or a keloid and cellulite or other conditions wherein excessive collagen is a problem.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: July 21, 2015
    Assignee: Johnson & Johnson Consumer Companies, Inc.
    Inventors: Kimberly Capone, Euen Thomas Graham Ekman Gunn, Diana Roshek Johnson, Russel Walters
  • Publication number: 20150140093
    Abstract: Compositions, methods of making, and methods of using nanoclusters in which the nanoclusters comprise a plurality of nanoparticles having a core of nanoparticles arranged such that the surfaces of the nanoparticles contact adjacent nanoparticles, the nanoparticles comprise an active ingredient, and the nanocluster has a mass median aerodynamic diameter of from about 0.25 ?m to about 20 ?m.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 21, 2015
    Inventors: Cory J. Berkland, Lianjun Shi, Nashwa El Gendy, Carl Plumley, Mark Bailey
  • Publication number: 20150132343
    Abstract: A method of treating a patient, comprising administering at least one antibiotic, e.g., doxycycline and ciprofloxacin, sufficient to substantially treat an intracellular bacterial organism present in at least erythrocytes, e.g., over a course of at least two weeks; and subsequently administering at least one immunostimulant, e.g., which directly or indirectly increases levels of immunostimulatory cytokines in the patient, and at least one antioxidant, e.g., glutathione, to effectively treat a coinfection of the patient with a virus. The intracellular bacterial organism may be a rickettsiales-like organism, and the virus may be HIV.
    Type: Application
    Filed: November 10, 2014
    Publication date: May 14, 2015
    Inventor: Luc Montagnier
  • Publication number: 20150133410
    Abstract: Embodiments of the invention provide aqueous pharmaceutical compositions suitable for topical administration to otic tissue, ocular tissue, nasal tissue, or a combination thereof that contain 0.02%-0.40% w/w of a ciprofloxacin, 0.01%-1.0% w/w of a surfactant, 0.05%-2.5% w/w of an acetic acid-acetate salt buffer, an amount of a tonicity agent sufficient to cause the composition to have an osmolality of about 275-325 mOsm, and water. In such embodiments, the compositions have a pH of from 5.0 to 5.3 and at least about 95% of the ciprofloxacin is in solution at room temperature.
    Type: Application
    Filed: November 14, 2013
    Publication date: May 14, 2015
    Inventors: Nilesh Parikh, William Hite
  • Publication number: 20150132386
    Abstract: A dry powder formulation comprising a combination of at least a first pharmaceutically active quinolone and a second pharmaceutically active quinolone.
    Type: Application
    Filed: May 21, 2013
    Publication date: May 14, 2015
    Inventors: Desmond Heng, Lee Sie Huey, Jeanette Teo, Wai Kiong Ng, Reginald Tan
  • Publication number: 20150132358
    Abstract: A method and apparatus for administering an active agent such as a medicine to a subject, uses an ocular implant such as a punctal plug, to which the active agent has been applied. The implant is installed at the eye of the subject for administering the active agent via tissues of the eye.
    Type: Application
    Filed: August 29, 2014
    Publication date: May 14, 2015
    Inventors: Steven A. Odrich, Liane C. Glazer
  • Publication number: 20150133409
    Abstract: Embodiments of he invention provide aqueous pharmaceutical compositions suitable for topical administration to otic tissue, ocular tissue, nasal tissue, or a combination thereof that contain 0.02%-0.40% w/w of a ciprofloxacin, 0.01%-1.0% w/w of a surfactant, 0.05%-2.5% w/w of an acetic acid-acetate salt buffer, an amount of a tonicity agent sufficient to cause the composition to have an osmolality of about 275-325 mOsm, and water. In such embodiments, the compositions have a pH of from 5.0 to 5.2 and at least about 97% of the ciprofloxacin is in solution at a temperature of 5° C.
    Type: Application
    Filed: November 14, 2013
    Publication date: May 14, 2015
    Inventors: Nilesh Parikh, William Hite
  • Patent number: 9028864
    Abstract: A concentrated inhalable formulation of an antibiotic drug such as ciprofloxacin is disclosed. The antibiotic is formulated with sodium acetate and liposome which incorporate antibiotic. The formulation is aerosolized and inhaled for treatment of respiratory tract infections and other medical conditions.
    Type: Grant
    Filed: September 22, 2010
    Date of Patent: May 12, 2015
    Assignee: Aradigm Corporation
    Inventors: David C. Cipolla, James Blanchard
  • Publication number: 20150110855
    Abstract: Methods for formulating and compositions of immediate and sustained release liposomal products which comprise a surfactant that interacts with liposomes to effect drug release therefrom, and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 23, 2015
    Inventors: David C. CIPOLLA, Igor GONDA
  • Publication number: 20150105337
    Abstract: The present invention provides novel enterobactin-cargo conjugates, such as compounds of Formula (I), and salts thereof, where X is the cargo and may be an antibiotic, a fluorophore, or biotin. The present invention also provides complexes, compositions, kits, and methods that involve the compounds of Formula (I) and are useful in delivering a cargo to a bacterium, treating a bacterial infection, cystic fibrosis, and/or inflammatory bowel disease in a subject, preventing a bacterial infection, cystic fibrosis, and/or inflammatory bowel disease in a subject, inhibiting the growth of or killing a bacterium, or determining the concentration of a bacterium in a biological sample. In certain embodiments, the bacterium is a Gram-negative bacterium.
    Type: Application
    Filed: October 16, 2014
    Publication date: April 16, 2015
    Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Elizabeth Marie Nolan, Tengfei Zheng, Phoom Chairatana
  • Publication number: 20150105376
    Abstract: The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments.
    Type: Application
    Filed: December 18, 2014
    Publication date: April 16, 2015
    Inventors: Jennifer X. Qiao, Carol Hui Hu, Tammy C. Wang
  • Patent number: 8999952
    Abstract: An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a ?-cyclodextrin, preferably, sulfobutyl ether ?-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or reducing irritation caused by aripiprazole at an intramuscular injection site and a method for treating schizophrenia employing the above formulation are also provided.
    Type: Grant
    Filed: April 29, 2013
    Date of Patent: April 7, 2015
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Manoj Nerurkar, Vijay H. Naringrekar
  • Publication number: 20150087886
    Abstract: This invention relates to novel cancer treatment compositions and associated therapeutic methods. More particularly, this invention relates in part to small chemical bifunctional inhibitors of DNA replication and repair proteins Metnase and/or Intnase (also termed Gypsy Integrase, Gypsy Integrease-1, Gypsy Retransposon Integrase 1, or GIN-1) that simultaneously damage DNA, and to a therapeutic method that utilizes the inhibitors to increase the effectiveness of cancer treatment protocols, including radiation therapy. In preferred embodiments, compounds, compositions and methods of treatment of the invention are used to treat a patient suffering from leukemia (e.g. acute myeloid leukemia (AML) and related cancers.
    Type: Application
    Filed: October 9, 2014
    Publication date: March 26, 2015
    Inventors: Robert Hromas, Andrei Leitao, Tudor I. Oprea, Larry A. Sklar, Elizabeth A. Williamson, Justin Wray, Wei Wang
  • Publication number: 20150079116
    Abstract: NK cell licensing predisposes patients to chronic inflammatory disease. Methods and kits to diagnose and treat chronic inflammatory disease based on genetic haplotype and cytokine profile are described herein.
    Type: Application
    Filed: April 11, 2013
    Publication date: March 19, 2015
    Inventors: Jonathan Braun, Lin Lin
  • Publication number: 20150080387
    Abstract: The invention relates to pharmaceutical formulations in liquid form, containing fluoroquinolones and antioxidative sulphur compounds. The formulations are particularly suitable for parenteral uses and are distinguished, inter alia, by good tolerance.
    Type: Application
    Filed: November 21, 2014
    Publication date: March 19, 2015
    Inventors: Iris HEEP, Kristine FRAATZ, Hans-Jürgen HAMANN, Markus EDINGLOH
  • Publication number: 20150071992
    Abstract: A concentrated inhalable formulation of an antibiotic drug such as ciprofloxacin is disclosed. The antibiotic is formulated with sodium acetate and liposome which incorporate antibiotic. The formulation is aerosolized and inhaled for treatment of respiratory tract infections and other medical conditions.
    Type: Application
    Filed: November 25, 2014
    Publication date: March 12, 2015
    Inventors: DAVID C. CIPOLLA, JAMES BLANCHARD
  • Patent number: 8975275
    Abstract: The invention relates to the use of chemotherapeutic agents for the production of a medicament for the topical and/or local treatment of diseases caused by bacteria and/or for prophylaxis in humans or animals.
    Type: Grant
    Filed: December 22, 2000
    Date of Patent: March 10, 2015
    Assignee: Bayer Innovation GmbH
    Inventors: Hans-Herrmann Schulz, Günther Schlimbach
  • Publication number: 20150050345
    Abstract: Processes for preparing micronized particles comprising a poorly water soluble bioactive agent are provided. The processes utilize a superheated aqueous phase which can serve as the continuous phase of an emulsion. The superheated aqueous phase can be used to melt poorly water soluble bioactive agents and/or matrix materials which them form molten droplets dispersed within the superheated aqueous phase. The size and size distribution of the molten droplets can be controlled using a variety of suitable methods. The molten droplets can then be cooled to form micronized particles comprising the poorly water soluble bioactive agent. If desired, the cooling rate can be selected to control the crystalline morphology of the resulting micronized particles.
    Type: Application
    Filed: August 13, 2014
    Publication date: February 19, 2015
    Inventors: Hugh D.C. Smyth, Matt Herpin
  • Publication number: 20150025086
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Application
    Filed: October 9, 2014
    Publication date: January 22, 2015
    Inventors: Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
  • Patent number: 8933016
    Abstract: It is an object of the present invention to provide antimicrobial metallodrugs comprising an antimicrobial peptide (“AMP”) and/or an antibiotic covalently bound to a metal binding moiety. These metallodrugs combine a metal binding domain which typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, with a member of a diverse class of antimicrobial agents currently validated in preclinical and clinical settings for the treatment of a broad spectrum of pathogenic organisms.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: January 13, 2015
    Assignee: MetalloPharm, LLC
    Inventors: James A. Cowan, Ada S. Cowan
  • Publication number: 20150005287
    Abstract: The present invention provides a compound represented by the formula (I) wherein X is a hydrogen atom or a fluorine atom; R is a hydrogen atom or alkyl; R1 is (1) cyclopropyl optionally substituted by to 3 halogen atoms or (2) phenyl optionally substituted by 1 to 3 halogen atoms; R2 is alkyl, alkoxy, haloalkoxy, a halogen atom, cyano, etc.; and R3 is 7-oxo-7,8-dihydro-1,8-naphthyridinyl, 3-pyridyl, etc., or a salt thereof. The compound of the present invention has excellent antimicrobial activity against Clostridium difficile and is useful for the prevention or treatment of intestinal infection such as Clostridium difficile-associated diarrhea.
    Type: Application
    Filed: February 28, 2014
    Publication date: January 1, 2015
    Inventors: Mamuti ABUDUSAIMI, Fangguo YE, Jiangqin SUN, Hisashi MIYAMOTO, Jay-Fei CHENG, Daisuke OKA
  • Publication number: 20140377361
    Abstract: A microparticle for drug delivery comprises an active agent and an excipient, the excipient comprising a metal ion-lipid complex. The metal ion is chosen from the group consisting of lanthanide metals, actinide metals, group IIa and IIIb metals, transition metals or mixtures thereof. The lipid comprises a phospholipid. The complex results in a glass transition temperature increase of the microparticle.
    Type: Application
    Filed: September 5, 2014
    Publication date: December 25, 2014
    Applicant: NOVARTIS AG
    Inventors: Luis A. DELLAMARY, Jean RIESS, Ernest G. SCHUTT, Jeffry G. WEERS, Thomas E. TARARA
  • Publication number: 20140378415
    Abstract: The present invention provides compounds of formula (I) wherein P is P0, heterocyclyl or heterocyclyl substituted by one to five Z formula (II); Y1, Y2, Y3 and Y4 are independently of each other C—H, C—R5, or nitrogen; G1 is oxygen or sulfur; X4 is C1-C8 haloalkyl; R4 is aryl or aryl substituted by one to five R9, or heteroaryl or heteroaryl substituted by one to five R9; and R1, R2, R4, R5, R9 and Z are as defined in the claims. The invention also provides compositions comprising the compounds of formula (I), intermediates useful in the preparation of compounds of formula (I) and methods of using the compounds of formula (I) to control insects, acarines, nematodes or molluscs.
    Type: Application
    Filed: August 27, 2012
    Publication date: December 25, 2014
    Applicant: SYNGENTA PARTICIPATIONS AG
    Inventors: Jerome Yves Cassayre, Myriem El Qacemi
  • Publication number: 20140363479
    Abstract: There is disclosed herein a composition for treating extracellular parasitic infections, the composition comprising one or more of the following combinations: at least one quinolone or fluoroquinolone together with at least one tetracycline, iodoquinol, an azole or imidazole; or at least two agents selected from the group consisting of iodoquinol, thiazolidones, tetracycline, nitroimidazoles, cotrimoxazole and diloxanide furoate.
    Type: Application
    Filed: August 21, 2014
    Publication date: December 11, 2014
    Inventors: Thomas Julius BORODY, Soledad CARSULA
  • Publication number: 20140363498
    Abstract: Some aspects of this disclosure relate to a method of treating an ophthalmic disease affecting an eye of a patient comprising forming a covalently-crosslinked hydrogel in situ at a peri-ocular, intra-ocular, or intra-vitreal site for controlled release of a therapeutic agent.
    Type: Application
    Filed: August 27, 2014
    Publication date: December 11, 2014
    Inventors: Amarpreet S. Sawhney, William H. Ransone, II
  • Patent number: 8901131
    Abstract: An ophthalmic gel of gatifloxacin and the preparation method thereof are disclosed. The gel comprises gatifloxacin or its pharmaceutical salts, matrix and water. Said matrix is one or more selected from carbomer, mixture of carbomer and HPMC, and sodium hyaluronate.
    Type: Grant
    Filed: November 23, 2010
    Date of Patent: December 2, 2014
    Assignee: Shenyang Xingqi Pharmaceutical Co., Ltd.
    Inventors: Jidong Liu, Yuchun Yang, Hai Tang
  • Publication number: 20140350028
    Abstract: A composition for pulmonary administration comprises a fluoroquinolone betaine, such as ciprofloxacin betaine, and an excipient. In one version, the particles have a mass median aerodynamic diameter from about 1 ?m to about 5 ?m, and the fluoroquinolone has a half life in the lungs of at least 1.5 hours. The composition is useful in treating an endobronchial infection, such as Pseudomonas aeruginosa, and is particularly useful in treating cystic fibrosis.
    Type: Application
    Filed: August 12, 2014
    Publication date: November 27, 2014
    Inventors: Jeffry Weers, Thomas Tarara
  • Publication number: 20140348787
    Abstract: Compositions and methods for treating ear infections are disclosed. More specifically, these methods may refer to treatment of internal otitis using an otic composition, such as otic gel for animals and humans. Poloxamer otic gel may be in liquid state at room temperature and may change to gel at about temperature (64° F.) as poloxamer otic gel reaches body temperature, because of the thermo-reversible properties. Consequently, poloxamer otic gel may be an effective treatment in animals and humans, where poloxamer otic gel may reach otitis affected site and remain there for a longer period of time. Additionally, poloxamer otic gel may include APIs such as antifungals, antibiotics and corticosteroids, among others. Furthermore, poloxamer otic gel may be instilled inside the ear, employing calibrated delivery device into the vertical ear canal in order to reach the horizontal ear canal, without puncturing the tympanic membrane.
    Type: Application
    Filed: May 22, 2013
    Publication date: November 27, 2014
    Applicant: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
    Inventor: Chris V. Simmons
  • Patent number: 8889733
    Abstract: Artonin I is reported to treat multi-drug resistant Staphlococcus infections.
    Type: Grant
    Filed: January 14, 2013
    Date of Patent: November 18, 2014
    Inventors: Muhammad Iqbal Choudhary, Saba Farooq, Atia-tul Wahab, Christian D. A. Fozing, Atta-ur Rahman
  • Patent number: 8889689
    Abstract: This invention relates to novel cancer treatment compositions and associated therapeutic methods. More particularly, this invention relates in part to small chemical bifunctional inhibitors of DNA replication and repair proteins Metnase and/or Intnase (also termed Gypsy Integrase, Gypsy Integrease-1, Gypsy Retransposon Integrase 1, or GIN-I) that simultaneously damage DNA, and to a therapeutic method that utilizes the inhibitors to increase the effectiveness of cancer treatment protocols, including radiation therapy. In preferred embodiments, compounds, compositions and methods of treatment of the invention are used to treat a patient suffering from leukemia (e.g. acute myeloid leukemia (AML) and related cancers.
    Type: Grant
    Filed: January 26, 2011
    Date of Patent: November 18, 2014
    Assignee: STC.UNM
    Inventors: Robert Hromas, Andrei Leitao, Tudor I. Oprea, Larry A. Sklar, Elizabeth A. Williamson, Justin Wray, Wei Wang
  • Publication number: 20140328896
    Abstract: Provided are methods and compositions for enhancing the gastrointestinal health of an animal in need thereof by administering a gastrointestinal health maintaining or improving amount of a composition comprising an effective amount of lactic acid. The administered composition may also comprise one or more prebiotic, probiotic, symbiotic, anti bacterial, or anti-diarrhea agents.
    Type: Application
    Filed: December 29, 2011
    Publication date: November 6, 2014
    Applicant: HILL'S PET NUTRITION, INC.
    Inventors: Dennis Jewll, Luis J. Montelongo, Sarah Martinez, Lynda Melendez
  • Patent number: 8853197
    Abstract: Compounds of Formula (I), their preparation and use in preventing or treating bacterial infection is disclosed.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: October 7, 2014
    Assignee: Wockhardt Ltd.
    Inventors: Mahesh Vithalbhai Patel, Prasad Keshav Deshpande, Satish Bhawasar, Sachin Bhagwat, Mohammad Alam Jafri, Amit Mishra, Laxmikant Pavase, Sunil Gupta, Rajesh Kale, Sanjeev Joshi
  • Patent number: 8846650
    Abstract: Aqueous suspension formulations containing dexamethasone and ciprofloxacin are disclosed for the treatment of middle ear infections in human patients having an open tympanic membrane.
    Type: Grant
    Filed: February 13, 2009
    Date of Patent: September 30, 2014
    Assignee: Novartis AG
    Inventors: G. Michael Wall, Peter J. Conroy
  • Publication number: 20140287028
    Abstract: The use of chemotherapeutic agents for the preparation of a medicament for the topical and/or local treatment of diseases caused by bacteria and/or for prophylaxis in humans or animals.
    Type: Application
    Filed: June 3, 2014
    Publication date: September 25, 2014
    Applicant: BAYER INNOVATION GMBH
    Inventors: Hans-Herrmann SCHULZ, Gunther SCHLIMBACH
  • Publication number: 20140271923
    Abstract: Patients inflicted with various clustering chronic diseases require treatment with multiple drugs having distinct mechanisms of action. Accordingly, patients with multiple conditions suffer from cumulative side effects of multiple drugs as well as drug-drug interactions. Embodiments, agents, compounds or drugs of the present invention, such as sesquiterpenes, e.g., Zerumbone, replace an equal or larger number of approved drugs during patient treatment. Examples of disorders prevented or ameliorated by administration of the formulations of this invention include but are not limited to inflammatory diseases that may be, oncological, genetic, ischemic, infectious, neurological, hematological, ophthalmological, rheumatoid, orthopedic, neurological, hematological, kidney, vascular, dermatological, gynecological, or obstetric.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 18, 2014
    Inventor: Christopher Brian Reid
  • Publication number: 20140271921
    Abstract: A topical composition comprises at least 5 wt % metronidazole or a pharmacologically acceptable derivative thereof in a non-aqueous vehicle. The composition may be used in the treatment of conditions of the colon, rectum, anorectum and perianal region, in particular inflammatory bowel disease and perianal Crohn's disease. The composition also relieves pain and inflammation and promotes healing of the colon, rectum, anorectum and perianal region following surgical operations. One advantage of the composition is that topical administration of metronidazole results in a primarily local effect and thus side effects observed from systemic administration are avoided.
    Type: Application
    Filed: May 28, 2014
    Publication date: September 18, 2014
    Applicant: SLA PHARMA AG
    Inventor: DAVID NIGEL ARMSTRONG
  • Publication number: 20140256661
    Abstract: The present invention relates to a pharmaceutical composition, in particular a composition formulated for enema administration, wherein the composition comprises metronidazole or a pharmacologically acceptable derivative thereof in an amount to effectively treat both acute and chronic pouchitis and/or proctitis.
    Type: Application
    Filed: July 12, 2012
    Publication date: September 11, 2014
    Inventor: David Nigel Armstrong
  • Publication number: 20140256666
    Abstract: The present invention describes single drug entities, formed by connecting an antibiotic moiety via a linker with a non-steroidal anti-inflammatory drug (NSAID) moiety. Upon topical application to the eye, the conjugate hybrid would undergo enzymatic and/or hydrolytic cleavage to release the individual antibiotic and NSAID drug.
    Type: Application
    Filed: March 6, 2014
    Publication date: September 11, 2014
    Applicant: Allergan, Inc.
    Inventors: Santosh C. Sinha, Smita S. Bhat, Ken Chow, LIMING WANG, MICHAEL E. GARST, MAYSSA ATTAR, BRANDON D. SWIFT
  • Publication number: 20140256658
    Abstract: The present invention describes antibiotic conjugates. These single drug entities are formed connecting one antibiotic with another antibiotic. Upon topical application to the eye, the conjugate hybrid would undergo enzymatic and/or hydrolytic cleavage to release the individual drugs.
    Type: Application
    Filed: March 6, 2014
    Publication date: September 11, 2014
    Applicant: Allergan, Inc.
    Inventors: Santosh C. Sinha, Smita S. Bhat, Ken Chow, LIMING WANG, MICHAEL E. GARST, MAYSSA ATTAR, BRANDON D. SWIFT
  • Patent number: 8822450
    Abstract: Compounds of Formula (I), their preparation and use in preventing or treating bacterial infection is disclosed.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: September 2, 2014
    Assignee: Wockhardt Ltd.
    Inventors: Mahesh Vithalbhai Patel, Prasad Keshav Deshpande, Satish Bhawsar, Sachin Bhagwat, Mohammed Alam Jafri, Amit Mishra, Laxmikant Pavase, Sunil Gupta, Rajesh Kale, Sanjeev Joshi
  • Publication number: 20140243314
    Abstract: The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments.
    Type: Application
    Filed: September 24, 2012
    Publication date: August 28, 2014
    Inventors: Jennifer X. Qiao, Carol Hui Hu, Tammy C. Wang
  • Publication number: 20140228359
    Abstract: The present invention relates to novel bis-indolic derivatives, processes for their preparation, and their potential use as new antibacterial drugs.
    Type: Application
    Filed: July 20, 2012
    Publication date: August 14, 2014
    Applicant: UNIVERSITE JOSEPH FOURIER
    Inventors: Jean-Noël Denis, Marcelle Claude Jolivalt, Louis Max Maurin, Nikolaevna Olga Burchak